John P. Clancy

Overview

Best Publications

• Effect of VX-770 in Persons with Cystic Fibrosis and the G551D-CFTR Mutation

  Frank J. Accurso;Steven M. Rowe;J. P. Clancy;Michael P. Boyle

  897
  Citations

• Recombinant human acid α-glucosidase Major clinical benefits in infantile-onset Pompe disease

  P. S. Kishnani;D. Corzo;M. Nicolino;B. Byrne

  874
  Citations

• Results of a phase IIa study of VX-809, an investigational CFTR corrector compound, in subjects with cystic fibrosis homozygous for the F508del-CFTR mutation

  J. P. Clancy;Steven M. Rowe;Frank J. Accurso;Moira L. Aitken

  639
  Citations

• A novel proteolytic cascade generates an extracellular matrix-derived chemoattractant in chronic neutrophilic inflammation.

  Amit Gaggar;Patricia L. Jackson;Brett D. Noerager;Philip J. O’Reilly

  427
  Citations

• SUPPRESSION OF A CFTR PREMATURE STOP MUTATION IN A BRONCHIAL EPITHELIAL CELL LINE

  David M. Bedwell;Anisa Kaenjak;Dale J. Benos;Zsuzsa Bebok

  395
  Citations

• Repeated adeno-associated virus serotype 2 aerosol-mediated cystic fibrosis transmembrane regulator gene transfer to the lungs of patients with cystic fibrosis: a multicenter, double-blind, placebo-controlled trial.

  Richard B. Moss;David Rodman;L. Terry Spencer;Moira L. Aitken

  376
  Citations

• Repeated aerosolized AAV-CFTR for treatment of cystic fibrosis: a randomized placebo-controlled phase 2B trial.

  Richard B Moss;Carlos Milla;John Colombo;Frank Accurso

  314
  Citations

• Evidence that Systemic Gentamicin Suppresses Premature Stop Mutations in Patients with Cystic Fibrosis

  J. P. Clancy;Zsuzsa Bebök;Fadel Ruiz;Chris King

  313
  Citations

• Phase II studies of nebulised Arikace in CF patients with Pseudomonas aeruginosa infection

  J P Clancy;L Dupont;M W Konstan;J Billings

  285
  Citations

• Early Treatment with Alglucosidase Alfa Prolongs Long Term Survival of Infants with Pompe Disease

  Priya S. Kishnani;Deya Corzo;Nancy D. Leslie;Daniel Gruskin

  268
  Citations

• A clinical inflammatory syndrome attributable to aerosolized lipid-DNA administration in cystic fibrosis.

  F. E. Ruiz;J. P. Clancy;M. A. Perricone;Z. Bebok

  265
  Citations

• A macromolecular complex of β2 adrenergic receptor, CFTR, and ezrin/radixin/moesin-binding phosphoprotein 50 is regulated by PKA

  Anjaparavanda P. Naren;Bryan Cobb;Chunying Li;Koushik Roy

  262
  Citations

• “CFTR Modulator Theratyping: Current Status, Gaps and Future Directions”

  John Paul Clancy;Calvin U. Cotton;Scott H. Donaldson;George M. Solomon

  254
  Citations

• Cystic fibrosis transmembrane conductance regulator facilitates ATP release by stimulating a separate ATP release channel for autocrine control of cell volume regulation

  Gavin M. Braunstein;Richard M. Roman;John P. Clancy;Brian A. Kudlow

  234
  Citations

• Airway microbiota across age and disease spectrum in cystic fibrosis

  Edith T. Zemanick;Brandie D. Wagner;Brandie D. Wagner;Charles E. Robertson;Richard C. Ahrens

  228
  Citations

• Failure of cAMP agonists to activate rescued ΔF508 CFTR in CFBE41o– airway epithelial monolayers

  Zsuzsa Bebok;James F. Collawn;John Wakefield;William Parker

  227
  Citations

• Cigarette Smoke Induces Systemic Defects in Cystic Fibrosis Transmembrane Conductance Regulator Function

  S. Vamsee Raju;Patricia L. Jackson;Clifford A. Courville;Carmel M. McNicholas

  196
  Citations

• Matrix metalloprotease-9 dysregulation in lower airway secretions of cystic fibrosis patients

  Amit Gaggar;Yao Li;Nathaniel Weathington;Margaret Winkler

  159
  Citations

• Sweat chloride as a biomarker of CFTR activity: Proof of concept and ivacaftor clinical trial data

  Frank J. Accurso;Fredrick Van Goor;Jiuhong Zha;Anne J. Stone

  153
  Citations

• Clinical Effectiveness of Elexacaftor/Tezacftor/Ivacaftor in People with Cystic Fibrosis.

  David P Nichols;David P Nichols;Alex C Paynter;Sonya L. Heltshe;Sonya L. Heltshe;Scott H Donaldson

  109
  Citations